Morgan Stanley Maintains Overweight on BeOne Medicines, Raises Price Target to $476

Benzinga · 15h ago
Morgan Stanley analyst Sean Laaman maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $465 to $476.